Resolving the daratumumab interference with blood compatibility testing

摘要

BACKGROUNDDaratumumab (DARA), a promising novel therapy for multiple myeloma, is an IgG1 monoclonal antibody that recognizes CD38 on myeloma cells. During routine compatibility testing, we observed that the plasma of five of five DARA-treated patients demonstrated a positive antibody screen and panreactivity on red blood cell (RBC) panel testing. We hypothesized that the observed panreactivity reflected DARA binding to CD38 on reagent RBCs, and we investigated methods to prevent this binding.